These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. [Immunoprophylaxis and immunotherapy of infection caused by Pseudomonas aeruginosa: research results and prospects]. Stanislavskiĭ ES; Joó I Zh Mikrobiol Epidemiol Immunobiol; 1983 Jul; (7):22-31. PubMed ID: 6414198 [No Abstract] [Full Text] [Related]
4. Opsonic activity of antisera to ribosomal vaccine fractions with live and formalinized Pseudomonas aeruginosa. Lieberman MM; Allen RC Can J Microbiol; 1986 Jun; 32(6):531-3. PubMed ID: 3089571 [TBL] [Abstract][Full Text] [Related]
5. Vaccines against Pseudomonas aeruginosa results and perspectives of investigations (survey). Joó I; Stanislavskii ES J Hyg Epidemiol Microbiol Immunol; 1982; 26(4):417-27. PubMed ID: 6819316 [TBL] [Abstract][Full Text] [Related]
6. Polysaccharide antigens of Pseudomonas aeruginosa. Knirel YA Crit Rev Microbiol; 1990; 17(4):273-304. PubMed ID: 1698385 [TBL] [Abstract][Full Text] [Related]
7. Molecular characterization of bacterial virulence factors and the consequences for vaccine design. The 1988 Fleming lecture. Dougan G J Gen Microbiol; 1989 Jun; 135(6):1397-406. PubMed ID: 2693598 [No Abstract] [Full Text] [Related]
8. [[Vaccine development for P. aeruginosa: based on antigen cloning of clinical vaccines][]. von Specht BU Zentralbl Chir; 1999; 124(4):298-302. PubMed ID: 10355084 [TBL] [Abstract][Full Text] [Related]
9. Pseudomonas aeruginosa. II. Experimental acellular vaccine of an endotoxin and anatoxin type. Bĕlohlávek S; Pavlík V; Rencová J; Stránský V; Nováková L; Sourek J; Výmola F J Hyg Epidemiol Microbiol Immunol; 1987; 31(3):343-52. PubMed ID: 3119704 [TBL] [Abstract][Full Text] [Related]
10. [Immunogenic properties and specificity of pseudomonas aeruginosa polyvalent vaccine]. Schiller B; Lysakowska E; Owczarska K Med Dosw Mikrobiol; 1981; 33(2):91-6. PubMed ID: 6170849 [No Abstract] [Full Text] [Related]
11. [Bacteria and bacterial vaccines as nonspecific modulators of immunological reactivity]. Prilepin NA; Semenov BF Zh Mikrobiol Epidemiol Immunobiol; 1980 Nov; (11):5-11. PubMed ID: 7004007 [No Abstract] [Full Text] [Related]
13. Application of vaccine technology to prevention of Pseudomonas aeruginosa infections. Pier G Expert Rev Vaccines; 2005 Oct; 4(5):645-56. PubMed ID: 16221066 [TBL] [Abstract][Full Text] [Related]
14. [Factors of Salmonella typhi virulence in relation to the development of new vaccines]. García JA; Paniagua J; Pelayo R; Isibasi A; Kumate J Salud Publica Mex; 1992; 34(3):262-7. PubMed ID: 1615345 [TBL] [Abstract][Full Text] [Related]
16. Studies on phagocytosis of mucoid and nonmucoid variants of Pseudomonas aeruginosa. I. Induction of homologous immunity by nonmucoid strains of P. aeruginosa. Gościniak G; Grzybek-Hryncewicz K Arch Immunol Ther Exp (Warsz); 1988; 36(2):177-84. PubMed ID: 2467637 [TBL] [Abstract][Full Text] [Related]
17. Bioengineering a bacterial pathogen to assemble its own particulate vaccine capable of inducing cellular immunity. Lee JW; Parlane NA; Wedlock DN; Rehm BH Sci Rep; 2017 Feb; 7():41607. PubMed ID: 28150705 [TBL] [Abstract][Full Text] [Related]
19. Antibody response to Pseudomonas aeruginosa surface protein antigens in a rat model of chronic lung infection. Cochrane DM; Brown MR; Anwar H; Weller PH; Lam K; Costerton JW J Med Microbiol; 1988 Dec; 27(4):255-61. PubMed ID: 3143837 [TBL] [Abstract][Full Text] [Related]
20. Strategies for development of universal vaccines against meningococcal serogroup B disease: the most promising options and the challenges evaluating them. Holst J Hum Vaccin; 2007; 3(6):290-4. PubMed ID: 17712231 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]